Cargando…
US FDA-approved therapeutic antibodies with high-concentration formulation: summaries and perspectives
Thirty four (34) of the total US FDA approved 103 therapeutic antibody drugs, accounts for one third of the total approved mAbs, are formulated with high protein concentration (100 mg/mL or above) which are the focus of this article. The highest protein concentration of these approved mAbs is 200 mg...
Autores principales: | Wang, Shawn Shouye, Yan, Yifei (Susie), Ho, Kin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8664682/ https://www.ncbi.nlm.nih.gov/pubmed/34909579 http://dx.doi.org/10.1093/abt/tbab027 |
Ejemplares similares
-
FDA Approval Summary: Midostaurin for the Treatment of Advanced Systemic Mastocytosis
por: Kasamon, Yvette L., et al.
Publicado: (2018) -
An insider's perspective on FDA approval of aducanumab
por: Wang, Yaning
Publicado: (2023) -
A review of FDA approved drugs and their formulations for the treatment of breast cancer
por: Chaurasia, Mohini, et al.
Publicado: (2023) -
FDA Approval Summary: Nivolumab for the Treatment of Relapsed or Progressive Classical Hodgkin Lymphoma
por: Kasamon, Yvette L., et al.
Publicado: (2017) -
THPdb: Database of FDA-approved peptide and protein therapeutics
por: Usmani, Salman Sadullah, et al.
Publicado: (2017)